Anne-Sophie Montero1, Suzanne Tran2, Aymeric Amelot1, Félix Berriat3, Guillaume Lot4, Stephan Gaillard5, Chiara Villa6,7,8,9, Marc Polivka10, Clovis Adam11, Ahmed Idbaih12, Loïc Feuvret13, Alexandre Carpentier1, Fabrice Parker14, Franck Bielle2,3, Bertrand Mathon15,16. 1. Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France. 2. Department of Neuropathology, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, Paris, France. 3. Inserm U 1127, CNRS UMR 7225, UMR S 1127, Paris Brain Institute, ICM, Sorbonne Université, 75013, Paris, France. 4. Department of Neurosurgery, Fondation Ophtalmologique Rothschild, Paris, France. 5. Department of Neurosurgery, Hôpital Foch, Suresnes, France. 6. INSERM U 1016, Institut Cochin, 75014, Paris, France. 7. NCRS UMR 8104, 75014, Paris, France. 8. Université Paris Descartes-Université de Paris, 75006, Paris, France. 9. Department of Pathological Cytology and Anatomy, Foch Hospital, 92151, Suresnes, France. 10. Department of Pathological Cytology and Anatomy, Lariboisière Hospital, APHP, 75010, Paris, France. 11. Department of Neuropathology, GHU Paris-Sud-Hôpital Bicêtre, le Kremlin-Bicêtre, France. 12. Inserm, CNRS, UMR S 1127, Institut du Cerveau Et de La Moelle Épinière, ICM, Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, 75013, Paris, France. 13. Department of Radiotherapy, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, Paris, France. 14. Department of Neurosurgery, Hôpitaux Universitaires Paris-Sud, AP-HP, Centre Hospitalier Universitaire Bicêtre, Paris, France. 15. Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France. bertrand.mathon@aphp.fr. 16. Inserm U 1127, CNRS UMR 7225, UMR S 1127, Paris Brain Institute, ICM, Sorbonne Université, 75013, Paris, France. bertrand.mathon@aphp.fr.
Abstract
PURPOSE: Myxopapillary ependymoma (MPE) is the most frequent tumor affecting the medullary conus. The surgical therapeutic management is still debated and only few studies have focused on the postoperative clinical outcome of patients. This study aimed to demonstrate long-term postoperative outcome and to assess the predictive factors of recurrence as well as the clinical evolution of these patients. METHODS: From 1984 to 2019, in four French centers, 101 adult patients diagnosed with MPE were retrospectively included. RESULTS: Median age at surgery was 39 years. Median tumor size was 50 mm and lesions were multifocal in 13% of patients. All patients benefited from surgery and one patient received postoperative radiotherapy. Gross total resection was obtained in 75% of cases. Sixteen percent of patients presented recurrence after a median follow-up of 70 months. Progression free survival at 5 and 10 years were respectively estimated at 83% and 79%. After multivariable analysis, sacral localization, and subtotal resection were shown to be independently associated with tumor recurrence. 85% of the patients had a favorable evolution concerning pain. 12% of the patients presented a postoperative deterioration of sphincter function and 4% of motor function. CONCLUSION: Surgery alone is an acceptable option for MPE patients. Patients with sacral location or incomplete resection are at high risk of recurrence and should be carefully monitored.
PURPOSE: Myxopapillary ependymoma (MPE) is the most frequent tumor affecting the medullary conus. The surgical therapeutic management is still debated and only few studies have focused on the postoperative clinical outcome of patients. This study aimed to demonstrate long-term postoperative outcome and to assess the predictive factors of recurrence as well as the clinical evolution of these patients. METHODS: From 1984 to 2019, in four French centers, 101 adult patients diagnosed with MPE were retrospectively included. RESULTS: Median age at surgery was 39 years. Median tumor size was 50 mm and lesions were multifocal in 13% of patients. All patients benefited from surgery and one patient received postoperative radiotherapy. Gross total resection was obtained in 75% of cases. Sixteen percent of patients presented recurrence after a median follow-up of 70 months. Progression free survival at 5 and 10 years were respectively estimated at 83% and 79%. After multivariable analysis, sacral localization, and subtotal resection were shown to be independently associated with tumor recurrence. 85% of the patients had a favorable evolution concerning pain. 12% of the patients presented a postoperative deterioration of sphincter function and 4% of motor function. CONCLUSION: Surgery alone is an acceptable option for MPE patients. Patients with sacral location or incomplete resection are at high risk of recurrence and should be carefully monitored.
Authors: Alessia Pica; Robert Miller; Salvador Villà; Sidney P Kadish; Yavuz Anacak; Huda Abusaris; Gokhan Ozyigit; Brigitta G Baumert; Renata Zaucha; Guy Haller; Damien C Weber Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-26 Impact factor: 7.038
Authors: Emily A Sloan; Jason Chiang; Javier E Villanueva-Meyer; Sanda Alexandrescu; Jennifer M Eschbacher; Wesley Wang; Manuela Mafra; Nasir Ud Din; Emily Carr-Boyd; Michael Watson; Michael Punsoni; Angelica Oviedo; Ahmed Gilani; Bette K Kleinschmidt-DeMasters; Dylan J Coss; M Beatriz Lopes; Corey Raffel; Mitchel S Berger; Susan M Chang; Alyssa Reddy; Biswarathan Ramani; Sean P Ferris; Julieann C Lee; Jeffrey W Hofmann; Soo-Jin Cho; Andrew E Horvai; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Fausto J Rodriguez; David W Ellison; Arie Perry; David A Solomon Journal: Brain Pathol Date: 2021-01-28 Impact factor: 6.508
Authors: Michael Bockmayr; Kim Harnisch; Lara C Pohl; Leonille Schweizer; Theresa Mohme; Meik Körner; Malik Alawi; Abigail K Suwala; Mario M Dorostkar; Camelia M Monoranu; Martin Hasselblatt; Annika K Wefers; David Capper; Jürgen Hench; Stephan Frank; Timothy E Richardson; Ivy Tran; Elisa Liu; Matija Snuderl; Lara Engertsberger; Martin Benesch; Andreas von Deimling; Denise Obrecht; Martin Mynarek; Stefan Rutkowski; Markus Glatzel; Julia E Neumann; Ulrich Schüller Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029